Methods of treating cancer with an anti-pd-l1 antibody

Abstract

The present disclosure relates to methods, uses, and kits related to treating cancers by administering an anti-PD-L1 antibody (e.g., atezolizumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered in 840 mg every 2 weeks or 1680 mg every 4 weeks for two or more cycles.

1 - 47 . (canceled) 
     
     
         48 . A method for treating a human patient having a cancer, wherein the method comprises administering to the patient atezolizumab at a dose of 1680 mg every 4 weeks. 
     
     
         49 . The method of  claim 48 , wherein the method comprises administering the atezolizumab by intravenous infusion. 
     
     
         50 . The method of  claim 48 , wherein the cancer is a locally advanced or a metastatic cancer. 
     
     
         51 . The method of  claim 48 , wherein the atezolizumab is administered as a first-line treatment. 
     
     
         52 . The method of  claim 48 , wherein the cancer is a lung cancer, a liver cancer, a melanoma, or a sarcoma. 
     
     
         53 . The method of  claim 52 , wherein the cancer is a lung cancer. 
     
     
         54 . The method of  claim 53 , wherein the lung cancer is a non-small cell lung cancer (NSCLC) or a small cell lung cancer (SCLC). 
     
     
         55 . The method of  claim 53 , wherein the lung cancer is a metastatic NSCLC, and wherein a tumor sample from the patient comprises (i) tumor-infiltrating immune cells that express PD-L1 and cover 10% or more of the tumor area and/or (ii) tumor cells that express PD-L1 and cover 50% or more of the total tumor cells in the sample, as assayed by immunohistochemistry (IHC). 
     
     
         56 . The method of  claim 53 , wherein the lung cancer is a metastatic NSCLC, and wherein the patient has (i) metastatic NSCLC and disease progression during or following platinum-containing chemotherapy, or (ii) has EGFR or ALK genomic tumor aberrations. 
     
     
         57 . The method of  claim 53 , wherein the lung cancer is an NSCLC, and wherein the method further comprises administering to the patient an additional therapeutic agent. 
     
     
         58 . The method of  claim 57 , wherein the additional therapeutic agent is a platinum-containing chemotherapy, a taxane, and/or an anti-VEGF antibody. 
     
     
         59 . The method of  claim 58 , wherein:
 (i) the chemotherapy is carboplatin;   (ii) the taxane is paclitaxel or nab-paclitaxel; and/or   (iii) the anti-VEGF antibody is bevacizumab.   
     
     
         60 . The method of  claim 53 , wherein the lung cancer is an extensive-stage SCLC (ES-SCLC). 
     
     
         61 . The method of  claim 53 , wherein the lung cancer is an ES-SCLC, and wherein the method further comprises administering to the patient a platinum-containing chemotherapy and a topoisomerase II inhibitor. 
     
     
         62 . The method of  claim 61 , wherein:
 (i) the platinum-containing chemotherapy is carboplatin; and   (ii) the topoisomerase II inhibitor is etoposide.   
     
     
         63 . The method of  claim 52 , wherein the cancer is a hepatocellular cancer, and wherein the method further comprises administering to the patient an anti-VEGF antibody. 
     
     
         64 . The method of  claim 63 , wherein the anti-VEGF antibody is bevacizumab. 
     
     
         65 . The method of  claim 52 , wherein the cancer is a melanoma, and wherein the method further comprises administering to the patient a RAF inhibitor and a MAPK extracellular regulated kinase I inhibitor. 
     
     
         66 . The method of  claim 65 , wherein:
 (i) the RAF inhibitor is vemurafenib; and   (ii) the MAPK extracellular regulated kinase I inhibitor is CI-1040.   
     
     
         67 . The method of  claim 48 , wherein the patient is an adult patient.